Clinical trial · Observational
Cognitive Assessments in Patients With Cancer Undergoing Chemotherapy
Feasibility Study of a Cognitive Assessment Tool During Systemic Chemotherapy for Cancer Patients
NCT01506440CI-TRIAL-00033576completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This pilot clinical trial studies cognitive assessments in patients with cancer undergoing chemotherapy. Questionnaires that measure cognitive changes during chemotherapy may help identify the side effects of chemotherapy.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Neoplasm | Malignant Neoplasm | ONTOLOGY_EXACT | 0.90 |
| Unspecified Adult Solid Tumor, Protocol Specific | Adult Solid Neoplasm | ALIAS | 0.85 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cognitive assessment | Procedure | — | UNRESOLVED |
| quality-of-life assessment | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Supportive Care (cognitive assessment)
- description
- Patients complete cognitive assessments, comprising HVLT-R, TMT-A, TMT-B, DSC, Animals, MoCA, and DST. Patients also complete the Beck Depression Inventory. Assessments are administered on day 1 of chemotherapy and at 6-8 weeks and 12-16 weeks after day 1 of chemotherapy.
- interventionNames
- Procedure: cognitive assessment
- Procedure: quality-of-life assessment
Primary outcomes (1)
- measure
- Operational and logistical feasibility of administering cognitive assessment battery in medical oncology clinic environment during administration of chemotherapy.
- timeFrame
- Baseline to 16 weeks after the start of chemotherapy
- description
- To determine whether cognitive assessment tools can be administered within the clinical and scheduling constraints of current chemotherapy administration practices.
Secondary outcomes (2)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 50 Years
Show eligibility criteria text
Inclusion Criteria: * Patients must have histologically or cytologically confirmed cancer * Patients are candidates for systemic chemotherapy for their cancer diagnosis * Life expectancy must be greater than 6 months * Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: * Patients who have had prior systemic chemotherapy in their lifetime * Patients with known brain metastases should be excluded from this clinical trial because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events * Patients may not be participating on any other study investigating cognitive function * Patients who are non-English speaking are ineligible * Patients with hematologic malignancies are ineligible * Patients with primary central nervous system malignancies are ineligible
References
Publications (0)
Data not yet available
No reference posted for this study.